Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents

NCT04916613 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT04916613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04916613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Recruiting
Start date
April 19, 2022
Completion date
September 30, 2037
Enrollment
300 (estimated)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic